EC

EcoR1 Capital Portfolio holdings

AUM $2.06B Turnover 46.34%
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+30.71%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$326M
AUM Growth
+$72.3M
Cap. Flow
-$3.11M
Cap. Flow %
-0.95%
Top 10 Hldgs %
66.65%
Holding
46
New
15
Increased
5
Reduced
6
Closed
15
Avg Time Held Equity + Options
0.4 years
Top 10 Avg Time Held Equity + Options
0.4 years
Top 20 Avg Time Held Equity + Options
0.5 years
Avg Time Held Equity only
0.4 years
Top 10 Avg Time Held Equity only
0.5 years
Top 20 Avg Time Held Equity only
0.5 years

Top Buys

Rank Stock Value
1
ARDX icon
Ardelyx
ARDX
+$13.7M
2
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$13.7M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$8.71M
4
DERM icon
Dermira, Inc.
DERM
+$8.05M
5
KA icon
Kineta, Inc. Common Stock
KA
+$8M

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$21.8M
2
CYTK icon
Cytokinetics
CYTK
+$13.5M
3
XLRN
Acceleron Pharma
XLRN
+$12.6M
4
ITCI icon
Intra-Cellular Therapies Inc.
ITCI
+$9.51M
5
EPZM
Epizyme, Inc
EPZM
+$7.73M

Sector Composition

Rank Sector Weight
1 Healthcare 79.95%
2 Miscellaneous 20.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
IRWD icon
1
Ironwood Pharmaceuticals
IRWD
$595M
$44.6M 13.69%
3,355,516
+453,558
+16% +$5.3M
2015 Q4
3 quarters
LKFT icon
2
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.93B
$32.4M 9.93%
500,576
+61,191
+14% +$3.45M
2015 Q4
3 quarters
BMY icon
3
CALL
Bristol-Myers Squibb
BMY
$121B
$27M 8.27%
+500,000
New +$32.1M
2016 Q3
0 quarters
ASMB icon
4
Assembly Biosciences
ASMB
$418M
$21.2M 6.51%
245,264
– –
2014 Q4
7 quarters
DERM icon
5
DELISTED
Dermira, Inc.
DERM
$17.7M 5.42%
522,000
+250,000
+92% +$8.05M
2016 Q2
1 quarter
ARDX icon
6
Ardelyx
ARDX
$824M
$17M 5.2%
+1,310,023
New +$13.7M
2016 Q3
0 quarters
KURA icon
7
Kura Oncology
KURA
$857M
$16.3M 5.01%
2,611,906
+146,620
+6% +$743K
2015 Q4
3 quarters
FPRX
8
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$15M 4.62%
+286,612
New +$13.7M
2016 Q3
0 quarters
KYNB icon
9
Kyntra Bio
KYNB
$22.3M
$14.2M 4.36%
27,447
-4,103
-13% -$1.93M
2014 Q4
7 quarters
GILD icon
10
CALL
Gilead Sciences
GILD
$190B
$11.9M 3.64%
150,000
– –
2015 Q3
4 quarters
AGN
11
CALL
DELISTED
Allergan plc
AGN
$11.5M 3.53%
50,000
– –
2016 Q2
1 quarter
AGIO icon
12
Agios Pharmaceuticals
AGIO
$1.85B
$10.6M 3.24%
+200,000
New +$8.71M
2016 Q3
0 quarters
KA icon
13
DELISTED
Kineta, Inc. Common Stock
KA
$9.39M 2.88%
+4,302
New +$8M
2016 Q3
0 quarters
EXAS icon
14
PUT
DELISTED
Exact Sciences
EXAS
$9.29M 2.85%
+500,000
New +$8.81M
2016 Q3
0 quarters
AKAO
15
DELISTED
Achaogen Inc
AKAO
$8.05M 2.47%
1,679,707
+107,999
+7% +$431K
2016 Q2
1 quarter
CYTK icon
16
Cytokinetics
CYTK
$8.82B
$7.77M 2.38%
846,654
-1,293,043
-60% -$13.5M
2015 Q4
3 quarters
KIN
17
DELISTED
Kindred Biosciences, Inc.
KIN
$7.15M 2.19%
1,432,765
– –
2014 Q4
7 quarters
SNDX icon
18
Syndax Pharmaceuticals
SNDX
$1.21B
$5.42M 1.66%
357,365
– –
2016 Q1
2 quarters
ONC icon
19
BeOne Medicines Ltd
ONC
$39.8B
$5.04M 1.55%
163,470
-11,910
-7% -$346K
2016 Q1
2 quarters
IRWD icon
20
CALL
Ironwood Pharmaceuticals
IRWD
$595M
$4.47M 1.37%
336,111
-358,200
-52% -$4.19M
2016 Q1
2 quarters
ASND icon
21
Ascendis Pharma A/S
ASND
$14.9B
$4.41M 1.35%
+219,200
New +$3.62M
2016 Q3
0 quarters
ONCE
22
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$4.12M 1.26%
+68,600
New +$3.95M
2016 Q3
0 quarters
ADVM icon
23
DELISTED
Adverum Biotechnologies
ADVM
$3.89M 1.19%
+94,626
New +$3.59M
2016 Q3
0 quarters
NBRV
24
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$3.87M 1.19%
2,196
-55
-2% -$106K
2015 Q3
4 quarters
NTLA icon
25
Intellia Therapeutics
NTLA
$1.6B
$3.42M 1.05%
200,858
-109,837
-35% -$2.13M
2016 Q2
1 quarter
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q3 2016 Portfolio in Review

As of Q3 2016, EcoR1 Capital held 46 positions worth $326M, up 28% from $254M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

EcoR1 Capital's Q3 2016 filing shows 15 new, 5 increased, 6 reduced and 15 closed positions. Its largest new stake was Ardelyx: 1,310,023 shares worth $17M. The largest sale was Travere Therapeutics, an estimated $21.8M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 86% a quarter earlier, followed by Miscellaneous.

  • EcoR1 Capital's largest Q3 2016 buy was Ardelyx: 1,310,023 shares worth $17M.
  • EcoR1 Capital added most to Dermira, Inc. in Q3 2016, an estimated $8.05M increase.
  • EcoR1 Capital's biggest Q3 2016 reduction was Cytokinetics, cutting an estimated $13.5M.
  • EcoR1 Capital fully exited Travere Therapeutics in Q3 2016, selling an estimated $21.8M.
  • EcoR1 Capital's ten largest holdings make up 67% of its $326M portfolio in Q3 2016.
  • EcoR1 Capital opened 15 new positions and closed 15 in Q3 2016.
  • EcoR1 Capital's portfolio value rose 28% quarter-over-quarter to $326M.

Based on EcoR1 Capital's 13F filing for Q3 2016, filed 14 Nov 2016.